TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03859102

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-operative Carbohydrate PreLoad drink
Description: Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Gabapentin pre-op
Description: One dose of Gabapentin pre-operatively, 300mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lansoprazole pre-op
Description: One dose of Lansoprazole pre-operatively, 30mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Paracetamol intra-operatively
Description: One dose of Paracetamol intra-operatively, 1gram intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexamethasone intra-operatively
Description: One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ondansetron intra-operatively
Description: One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infiltration of surgical wounds with local anaesthetic
Description: Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium intra-operatively
Description: One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-operative Gabapentin analgesia
Description: Post-operative oral Gabapentin 300mg, three times daily as an analgesic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-operative oral Paracetamol analgesia
Description: Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-operative Ondansetron anti-emesis
Description: Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early extubation
Description: Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early mobilisation/physiotherapy
Description: Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encourage early oral food intake
Description: Patients will be encouraged to start eating as soon as possible post-operatively
Study: NCT04418310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lay open and curettage
Description: Lay open and curettage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic (E.P.Si.T) method
Description: Endoscopic (E.P.Si.T) method
Study: NCT02409979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide method
Description: Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange-CO2
Description: Insertion using water exchange, withdrawal using CO2 insufflation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange-AI
Description: Insertion using water exchange, withdrawal using air insufflation.
Study: NCT01034423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sun flower oil
Description: Capsules with sun flower oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sun flower oil
Description: Capsules with sun flower oil.
Study: NCT01592838

Intervention type: OTHER
Intervention: Data collection
Description: The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
Study: NCT01414296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: PSMA ADC administered IV
Study: NCT03692806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stablor
Description: Stablor sachet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sachet
Study: NCT02709369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIRREM
Description: HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
Study: NCT04229576

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENs
Description: Assessing the efficacy of TENs in pain relieve during office hysteroscopy .

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENs
Description: Assessing the efficacy of TENs in pain relieve during office hysteroscopy .
Study: NCT02371005

Intervention type: RADIATION
Group type: OTHER
Intervention: Cone Beam Computed Tomography (CBCT)

Intervention type: RADIATION
Group type: OTHER
Intervention: Cone Beam Computed Tomography (CBCT)
Study: NCT03514602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention
Description: Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only control
Description: The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists.
Study: NCT01260506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
Study: NCT03104803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term paired associative stimulation
Description: Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
Study: NCT03318068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
Study: NCT03003689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing
Description: Standard of care scaling and root planing using hand instruments and ultrasonic scaler

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Standard of care scaling and root planing using hand instruments and ultrasonic scaler

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
Study: NCT02753673

Intervention type: BEHAVIORAL
Intervention: qualitative interviews with patients

Intervention type: BEHAVIORAL
Intervention: questionnaires
Study: NCT03783806

Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography measurements
Description: Determination of functional status, Posturography measurements, postural tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography measurements
Description: Determination of functional status, Posturography measurements, postural tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography measurements
Description: Determination of functional status, Posturography measurements, postural tests
Study: NCT03907436

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: USDA Diet
Description: Participants will receive counseling and education on USDA Guidelines for Americans, 2010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will receive counseling and education on a Mediterranean diet.
Study: NCT01334775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open anterior inguinal hernia repair
Description: Placement of a surgical mesh in open anterior inguinal hernia repair.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open anterior inguinal hernia repair
Description: Placement of a surgical mesh in open anterior inguinal hernia repair.
Study: NCT06356493

Intervention type: PROCEDURE
Intervention: caesarean hysterectomy with prior placement of prophylactic occlusion balloons of both internal iliac arteries
Description: Preoperative placement of prophylactic occlusion balloons of both internal iliac arteries (OBIIA) was performed at radiology department. Access to the internal iliac arteries was achieved by retrograde transcutaneous introduction of hydrophilic sheath kits of 8.5 mm under fluoroscopic guidance from both femoral arteries. Once in the lumens of the two internal iliac arteries, the radiologist inflated the balloons until blood flow ceased. The pressure at which occlusion of both internal iliac arteries was achieved was recorded for subsequent replication in the operating room. The radiologist secured the two kits to the skin and applied a compressive dressing. The patient was then directly transferred to the operating room.

Intervention type: PROCEDURE
Intervention: caesarean hysterectomy without prior placement of prophylactic occlusion balloons of both internal iliac arteries
Description: Caesarean hysterectomy was performed through a midline infraumbilical incision. The bladder-uterine peritoneum was dissected, followed by a vertical fundal hysterotomy away from the placenta, and the baby was delivered This was followed by clamping the umbilical cord and closure of the hysterotomy while leaving the placenta in situ without any attempt at traction or delivery and without oxytocin administration.~We proceeded with the remaining steps of hysterectomy.
Study: NCT02242630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, 20 mg
Description: Compared with intrabursal triamcinolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, 40 mg
Description: Compared with intrabursal triamcinolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone, 20 mg
Description: Compared with methylprednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone, 40 mg
Description: Compared with methylprednisolone
Study: NCT02869035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
Study: NCT03639415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increasing the Controlled-Release Oxycodone dose frequency
Description: Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
Study: NCT01188447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canadian C-Spine Rule
Description: Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
Study: NCT00724893

Intervention type: BIOLOGICAL
Intervention: PegIFN-2b
Description: PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling

Intervention type: BIOLOGICAL
Intervention: PegIFN-2b
Description: PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin capsules administered orally. Dosing in accordance with approved labelling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
Study: NCT00592111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPP/ABV
Description: 4 courses of COPP/ABV hybrid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPP/ABV
Description: 6 courses of COPP/ABV hybrid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive chemo with concurrent growth factor
Description: 6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
Study: NCT02657941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational group
Description: Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational group
Description: Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions
Study: NCT02313714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),
Description: All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: very low electric muscular stimulation
Study: NCT03386227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withholding antibiotic prophylaxis
Description: Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
Study: NCT00559000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDNET
Description: Narrative Exposure Therapy for Children
Study: NCT03557944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reduction
Description: Systematic approach to reduction in polypharmacy.
Study: NCT03188185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Samidorphan + buprenorphine, administered sublingually

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALKS 5461 Placebo
Description: Placebo tablet, administered sublingually
Study: NCT03144999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVCAGsCD59
Description: AAVCAGsCD59 is administered as a single intravitreal injection in an office setting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVCAGsCD59
Description: AAVCAGsCD59 is administered as a single intravitreal injection in an office setting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVCAGsCD59
Description: AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
Study: NCT00581204

Intervention type: DEVICE
Intervention: Near-Infrared Diffuse Optical Spectroscopy
Description: Early predictor of hemorrhagic shock
Study: NCT04028505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin Injectable Product
Description: Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin Injectable Product
Description: Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH.
Study: NCT00859118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
Study: NCT00661440

Intervention type: DRUG
Group type: OTHER
Intervention: Neramexane mesylate
Description: 2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day

Intervention type: DRUG
Group type: OTHER
Intervention: Neramexane mesylate
Description: 2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
Study: NCT02622685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP10292
Description: Drug: DWP10292 tablets, oral administration, multiple administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP10292 Placebo
Description: Placebo tablets, oral administration, multiple administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Description: Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA Placebo
Description: Placebo tablets, oral administration, multiple administrations
Study: NCT04767750

Intervention type: OTHER
Intervention: Blood sample collection
Description: 5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~* Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~* Total RNA extraction from PBMCs by Trizol reagent and spin column.~* Reverse transcription to cDNA.~* The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR

Intervention type: OTHER
Intervention: Blood sample collection
Description: 5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~* Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~* Total RNA extraction from PBMCs by Trizol reagent and spin column.~* Reverse transcription to cDNA.~* The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR
Study: NCT02940002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
Study: NCT02884635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.